Weighted Average Number of Shares Outstanding, Diluted of Nabriva Therapeutics plc from 31 Dec 2014 to 30 Jun 2023

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Nabriva Therapeutics plc quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2014 to 30 Jun 2023.
  • Nabriva Therapeutics plc Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Jun 2023 was 3,230,827, a 28% increase year-over-year.
  • Nabriva Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 2,681,968, a 55% increase from 2021.
  • Nabriva Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 1,733,978, a 237% increase from 2020.
  • Nabriva Therapeutics plc annual Weighted Average Number of Shares Outstanding, Diluted for 2020 was 513,804, a 93% decline from 2019.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Nabriva Therapeutics plc Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 3,230,827 +701,304 +28% 01 Apr 2023 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 3,201,495 +849,729 +36% 01 Jan 2023 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 2,681,968 +947,990 +55% 01 Oct 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
Q3 2022 2,732,749 +711,679 +35% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 2,529,523 -38,044,325 -94% 01 Apr 2022 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 2,351,766 -24,061,824 -91% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q4 2021 1,733,978 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
Q3 2021 2,021,070 -12,448,020 -86% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 40,573,848 +29,296,023 +260% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 26,413,590 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 14,469,090 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 11,277,825 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2017 2,720,423 +602,528 +28% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q1 2016 2,117,895 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1

Nabriva Therapeutics plc Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 2,681,968 +947,990 +55% 01 Jan 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
2021 1,733,978 +1,220,174 +237% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
2020 513,804 -6,906,144 -93% 01 Jan 2020 31 Dec 2020 10-K 17 Apr 2023 2022 FY
2019 7,419,948 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
2016 2,147,832 +1,089,437 +103% 01 Jan 2016 31 Dec 2016 10-K 24 Mar 2017 2016 FY
2015 1,058,395 +733,692 +226% 01 Jan 2015 31 Dec 2015 10-K 24 Mar 2017 2016 FY
2014 324,703 01 Jan 2014 31 Dec 2014 10-K 24 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.